BIO (Bio-Rad Laboratories) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIO Bio-Rad Laboratories Inc BIO
70 GF Score
Price $376.41
GF Value $316.02
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bio-Rad Laboratories  (NYSE:BIO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bio-Rad Laboratories Cyclically Adjusted PS Ratio Related Terms


Bio-Rad Laboratories Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Cyclically Adjusted PS Ratio Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.77 4.58 3.42 3.42 3.07

Bio-Rad Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.44 2.81 3.05 2.75 2.87

BIO vs PODD, GKOS, GMED: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Cyclically Adjusted PS Ratio falls into.


BIO
70GF Score
Bio-Rad Laboratories Inc BIO
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bio-Rad Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Bio-Rad Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=24.278/333.9520*333.9520
=24.278

Current CPI (Jun. 2026) = 333.9520.

Bio-Rad Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 17.146 241.428 23.717
201612 19.337 241.432 26.747
201703 16.718 243.801 22.900
201706 16.819 244.955 22.930
201709 17.774 246.819 24.049
201712 20.636 246.524 27.954
201803 18.280 249.554 24.462
201806 19.058 251.989 25.257
201809 17.996 252.439 23.807
201812 20.669 251.233 27.474
201903 18.402 254.202 24.175
201906 18.990 256.143 24.759
201909 18.794 256.759 24.444
201912 20.662 256.974 26.851
202003 18.931 258.115 24.493
202006 17.861 257.797 23.137
202009 21.484 260.280 27.565
202012 26.180 260.474 33.565
202103 24.077 264.877 30.356
202106 23.747 271.696 29.188
202109 24.717 274.310 30.091
202112 24.489 278.802 29.333
202203 23.388 287.504 27.166
202206 23.196 296.311 26.143
202209 22.897 296.808 25.762
202212 24.513 296.797 27.582
202303 22.753 301.836 25.174
202306 23.203 305.109 25.396
202309 21.631 307.789 23.470
202312 23.640 306.746 25.737
202403 21.404 312.332 22.886
202406 22.486 314.175 23.901
202409 23.217 315.301 24.590
202412 23.842 315.605 25.228
202503 20.941 319.799 21.868
202506 23.931 322.561 24.776
202509 24.254 324.800 24.937
202512 25.663 324.054 26.447
202603 21.964 330.213 22.213
202606 24.278 333.952 24.278

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bio-Rad Laboratories (BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued. The current stock price of $376.41 is trading 19.1% above its estimated GF Value™ of $316.02. GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.

Key valuation signals for BIO:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $316.02 vs. price of $376.41 (19.1% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Other Exchanges BIO.B:USABUWA:Germany
Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
70GF Score

Get the complete analysis for BIO

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$376.41
Price
$316.02
GF Value